Inventor · disambiguated record
Ruichao Shen
Also filed as: SHEN RUICHAO · SHEN RUICHAO RICHARD
53 granted patents·15 pending applications·237 citations·filing 2005–2025
98Inventor score
Files withENANTA PHARM INC57BRONK BRIAN SCOTT7BETH ISRAEL HOSPITAL1HEPAITECH BEIJING BIOPHARMA TECH CO LTD1SATORI PHARMACEUTICALS INC1
Top patents by PatentIndex Score
68 records- 0198US11560368B2Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereofENANTA PHARM INC·Filed 2021·Granted Jan 24, 2023·6 cites·18 claims
- 0298US11384090B2Spiropyrrolidine derived antiviral agentsENANTA PHARM INC·Filed 2021·Granted Jul 12, 2022·14 cites·15 claims
- 0398US11352363B1Spiropyrrolidine derived antiviral agentsENANTA PHARM INC·Filed 2021·Granted Jun 7, 2022·13 cites·9 claims
- 0498US11339170B1Spiropyrrolidine derived antiviral agentsENANTA PHARM INC·Filed 2021·Granted May 24, 2022·17 cites·18 claims
- 0598US11325916B1Spiropyrrolidine derived antiviral agentsENANTA PHARM INC·Filed 2021·Granted May 10, 2022·16 cites·15 claims
- 0698US10683279B2Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereofENANTA PHARM INC·Filed 2018·Granted Jun 16, 2020·13 cites·18 claims
- 0797US11420976B2Heterocyclic compounds as anti-viral agentsENANTA PHARM INC·Filed 2021·Granted Aug 23, 2022·7 cites·23 claims
- 0897US10988458B2Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereofENANTA PHARM INC·Filed 2020·Granted Apr 27, 2021·7 cites·23 claims
- 0996US11919910B2Spiropyrrolidine derived antiviral agentsENANTA PHARM INC·Filed 2022·Granted Mar 5, 2024·5 cites·13 claims
- 1096US11912714B2Spiropyrrolidine derived antiviral agentsENANTA PHARM INC·Filed 2022·Granted Feb 27, 2024·6 cites·13 claims
- 1195US10968249B2Bile acid derivatives as FXR/TGR5 agonists and methods of use thereofENANTA PHARM INC·Filed 2020·Granted Apr 6, 2021·3 cites·12 claims
- 1295US10683289B2Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereofENANTA PHARM INC·Filed 2019·Granted Jun 16, 2020·10 cites·19 claims
- 1395US10450301B2Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereofENANTA PHARM INC·Filed 2018·Granted Oct 22, 2019·11 cites·20 claims
- 1495US10246439B2Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereofENANTA PHARM INC·Filed 2018·Granted Apr 2, 2019·12 cites·20 claims
- 1594US12018017B2Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereofENANTA PHARM INC·Filed 2022·Granted Jun 25, 2024·1 cites·14 claims
- 1694US11834436B2Tetrazole containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereofENANTA PHARM INC·Filed 2021·Granted Dec 5, 2023·2 cites·5 claims
- 1794US10450306B2Isoxazole analogs as FXR agonists and methods of use thereofENANTA PHARM INC·Filed 2017·Granted Oct 22, 2019·7 cites·22 claims
- 1894US10253018B2Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereofENANTA PHARM INC·Filed 2018·Granted Apr 9, 2019·10 cites·26 claims
- 1993US10696713B2Bile acid derivatives as FXR/TGR5 agonists and methods of use thereofENANTA PHARM INC·Filed 2018·Granted Jun 30, 2020·3 cites·15 claims
- 2092US10208081B2Bile acid derivatives as FXR/TGR5 agonists and methods of use thereofENANTA PHARM INC·Filed 2015·Granted Feb 19, 2019·9 cites·53 claims
- 2191US10457703B2Bile acid derivatives as FXR/TGR5 agonists and methods of use thereofENANTA PHARM INC·Filed 2016·Granted Oct 29, 2019·8 cites·16 claims
- 2290US10597382B2Tetrazole containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereofENANTA PHARM INC·Filed 2018·Granted Mar 24, 2020·10 cites·17 claims
- 2390US7649014B2Genipin derivatives and uses thereofBETH ISRAEL HOSPITAL·Filed 2005·Granted Jan 19, 2010·10 cites·10 claims
- 2489US11718641B2Bile acid derivatives as FXR/TGR5 agonists and methods of use thereofENANTA PHARM INC·Filed 2021·Granted Aug 8, 2023·1 cites·5 claims
- 2589US11040998B2Bile acid derivatives as FXR/TGR5 agonists and methods of use thereofENANTA PHARM INC·Filed 2019·Granted Jun 22, 2021·2 cites·17 claims
- 2688US11958879B2Bile acid derivatives as FXR/TGR5 agonists and methods of use thereofENANTA PHARM INC·Filed 2021·Granted Apr 16, 2024·1 cites·5 claims
- 2788US10080743B2Isoxazole derivatives as FXR agonists and methods of use thereofENANTA PHARM INC·Filed 2017·Granted Sep 25, 2018·4 cites·22 claims
- 2887US10472386B2Bile acid derivatives as FXR agonists and methods of use thereofENANTA PHARM INC·Filed 2018·Granted Nov 12, 2019·6 cites·10 claims
- 2987US10080742B2Isoxazole derivatives as FXR agonists and methods of use thereofENANTA PHARM INC·Filed 2017·Granted Sep 25, 2018·3 cites·24 claims
- 3085US12281140B2Bile acid derivatives as FXR/TGR5 agonists and methods of use thereofENANTA PHARM INC·Filed 2023·Granted Apr 22, 2025·0 cites·8 claims
- 3185US10149835B2Isoxazole derivatives as FXR agonists and methods of use thereofENANTA PHARM INC·Filed 2017·Granted Dec 11, 2018·2 cites·18 claims
- 3285US10080741B2Isoxazole derivatives as FXR agonists and methods of use thereofENANTA PHARM INC·Filed 2017·Granted Sep 25, 2018·3 cites·19 claims
- 3384US12459923B2Tetrazole containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereofENANTA PHARM INC·Filed 2023·Granted Nov 4, 2025·0 cites·12 claims
- 3482US10689391B2Isoxazole analogs as FXR agonists and methods of use thereofENANTA PHARM INC·Filed 2018·Granted Jun 23, 2020·2 cites·22 claims
- 3581US11008304B2Tetrazole containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereofENANTA PHARM INC·Filed 2019·Granted May 18, 2021·1 cites·6 claims
- 3680US10144729B2Isoxazole analogs as FXR agonists and methods of use thereofENANTA PHARM INC·Filed 2017·Granted Dec 4, 2018·2 cites·20 claims
- 3780US8093288B2Genipin derivatives and uses thereofZHANG CHEN-YU·Filed 2009·Granted Jan 10, 2012·5 cites·14 claims
- 3880US2024327452A1Bile Acid Derivatives as FXR/TGR5 Agonists and Methods of Use ThereofENANTA PHARM INC·Filed 2024·Application pending·0 cites
- 3976US11034684B2Isoxazole analogs as FXR agonists and methods of use thereofENANTA PHARM INC·Filed 2019·Granted Jun 15, 2021·1 cites·22 claims
- 4074US10138228B2Isoxazole derivatives as FXR agonists and methods of use therofENANTA PHARM INC·Filed 2017·Granted Nov 27, 2018·1 cites·18 claims
- 4173US10829486B2Isoxazole derivatives as FXR agonists and methods of use thereofENANTA PHARM INC·Filed 2019·Granted Nov 10, 2020·1 cites·21 claims
- 4272US10597391B2Urea-containing isoxazole derivatives as FXR agonists and methods of use thereofENANTA PHARM INC·Filed 2017·Granted Mar 24, 2020·1 cites·25 claims
- 4371US12384753B217-beta-hydroxysteroid dehydrogenase type 13 inhibitors and methods of use thereofENANTA PHARM INC·Filed 2022·Granted Aug 12, 2025·0 cites·6 claims
- 4470US2025376452A117-Beta-Hydroxysteroid Dehydrogenase Type 13 Inhibitors and Methods of Use ThereofENANTA PHARM INC·Filed 2025·Application pending·0 cites
- 4568US10266560B2Bile acid analogs as FXR/TGR5 agonists and methods of use thereofENANTA PHARM INC·Filed 2015·Granted Apr 23, 2019·1 cites·16 claims
- 4665US12006291B2Processes for the preparation of 4,6,7-trifluoro-1H-indole-2-carboxylic acidENANTA PHARM INC·Filed 2023·Granted Jun 11, 2024·0 cites·7 claims
- 4762US2023159546A1Novel spiropyrrolidine derived antiviral agentsENANTA PHARM INC·Filed 2022·Application pending·0 cites
- 4862US2023295175A1Processes for the preparation of substituted spirooxindole derivativesENANTA PHARM INC·Filed 2023·Application pending·0 cites
- 4961US2025326777A1Compounds, compositions and methods thereofHEPAITECH BEIJING BIOPHARMA TECH CO LTD·Filed 2023·Application pending·0 cites
- 5060US11945824B2Heterocyclic compounds as anti-viral agentsENANTA PHARM INC·Filed 2021·Granted Apr 2, 2024·0 cites·21 claims
Showing the top 50 of 68 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Ruichao Shen files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →